Abstract Circadian rhythms are generated through a transcription-translation feedback loop involving clock genes and the casein kinases CSNK1D and CSNK1E. In this study, we investigated the effects of the casein kinase inhibitor PF-670462 (50 mg/kg) on rhythmic expression of clock genes in the liver, pancreas and suprachiasmatic nucleus (SCN) as well as plasma corticosterone, melatonin and running behaviour in rats and compared them to the responses to a 4 h extension of the light phase. PF-670462 acutely phase delayed the rhythmic transcription of Bmal1, Per1, Per2 and Nr1d1 in both liver and pancreas by 4.5 ± 1.3 and 4.5 ± 1.2 h, respectively, 1 day after administration. In the SCN, the rhythm of Nr1d1 and Dbp mRNA expression was delayed by 4.2 and 4 h, respectively. Despite these changes, the time of peak plasma melatonin secretion was not delayed, although the plasma corticosterone rhythm and onset of wheel-running activity were delayed by 2.1 and 1.1 h, respectively. These changes are in contrast to the effects of the 4 h light extension, which resulted in delays in peak expression of the clock genes of less than 1 h and no change in the melatonin or corticosterone rhythms. The ability of the casein kinase inhibitor to bring about large phase shifts in the rhythms of major metabolic target tissues may lead to new drugs being developed to rapidly phase adjust circadian rhythms to alleviate the metabolic impact of shift work.
Introduction
The circadian timing system of animals ensures that a wide range of physiological processes are appropriately timed across the day and night. In mammals, the suprachiasmatic nucleus (SCN) is the site of the master biological clock with its endogenous rhythmicity generated through clock gene transcription factors [1] . Through a transcriptiontranslation feedback loop (TTFL) system, the cycle of gene expression has a period close to 24 h. The retinae are connected to the SCN via the optic nerve such that the TTFL system in the SCN is entrained to the solar day/night cycle. The SCN then alters a range of physiological systems via neuronal and hormonal output signals to the rest of the body [2] allowing the organism to respond to changes in season, trans-meridian travel or shift work. One such important neural pathway is a multisynaptic connection to the pineal gland which influences its production of the hormone melatonin [3] . Acute exposure to light during the night suppresses the production of melatonin in an intensity and wavelength dependent manner. The same light exposure also causes the induction of genes that are part of the TTFL system in the SCN resulting in a shift in the phase of the endogenous rhythm on subsequent cycles. The impact of the light is temporally gated such that exposure during the early dark period will delay the phase of the SCN rhythm, whereas light during the late dark period will result in an advance in the rhythm. An interesting feature of the circadian timing system and its response to light is that even under the most favourable experimental conditions, the largest acute phase shifts achieved with bright light are up to 4 h [4] [5] [6] [7] [8] [9] [10] and vary with the timing and duration of the light pulse [11] . As a consequence, to shift rhythms by 12 h as required with transmeridian travel, can take many days to achieve. Furthermore, there is growing evidence that during lightinduced phase shifting, the SCN and its peripheral targets respond at different rates, with liver and muscle taking up to a week to fully adapt to even moderate changes in lighting conditions [12] . A likely cause for this disconnection is the presence of an entrainable clock TTFL system in virtually all other cells and organs.
The basis of cellular rhythmicity in the SCN and peripheral organs has been extensively researched, and while new modulators are still being discovered, the core mechanism operating in mammals is quite clear [13] . In brief, the transcription factors CLOCK/BMAL1 drive the expression of the period genes (Per1 and Per2) and the cryptochrome genes (Cry1 and Cry2). The period and cryptochrome proteins in turn repress the CLOCK/BMAL1 induction of their own transcription, thereby creating a negative feedback loop. An accessory loop involving NR1D1 (REV ERB alpha) and NR1F1 (ROR alpha) repress or induce, respectively, Bmal1 gene expression to help the process to be self-sustaining. Stability of the proteins involved in the TTFL is a key factor in the maintenance of the near 24 h cyclicity found in all organisms. In particular phosphorylation of the period proteins, which primes them as targets for degradation, is a key event.
The casein kinases CSNK1D and CSNK1E have a pivotal role in ensuring that clock gene expression is rhythmic by phosphorylating the Period proteins and thereby marking them for subsequent degradation [14, 15] . Inhibition of the enzymes results in retention of nuclear PER protein [16] , leading to prolonged repression of Per and Cry gene expression, effectively delaying the cycle until the inhibition of the enzyme wanes and the PER/CRY complex finally degrades. The potent casein kinase 1d/e inhibitor PF-670462 has been shown to delay rhythms in an alga [17] , Neurospora [18] , a marine crustacean [19] , zebra fish [20] , rats [21, 22] , mice [16, 23, 24] and cymologous monkeys [25] . The widespread cross species effects of casein kinase inhibition is clear evidence of its conservation as an integral component of the circadian timing system. While PF-670462 is considered primarily a casein kinase inhibitor, there is the potential for inhibition of other kinases including PKACa (protein kinase A catalytic subunit), p38 cascade (p38 cascade, p38 coupled to MAPKAPK2), HGK (HPK/GCK-like kinase), LCK (lymphocyte-specific protein tyrosine kinase) and EGFR (epidermal growth factor receptor tyrosine kinase) [23] . The effects of PF-670462 inhibition of casein kinase have been studied at the cellular level of mammals using PER2::Luc reporters [16, 23] and clock gene expression in the whole hypothalamus [24] , but there have been no studies addressing the effects of in vivo CSNK1D and CSNK1E inhibition on clock gene expression in key organs or hormone secretion.
In this study, we investigated the effect of a single dose of PF-670462 administered at the time of lights off on rhythmic clock gene expression in the liver, pancreas and SCN over the subsequent 36 h. We chose the liver and pancreas because of the critical role rhythms in these organs have in maintaining metabolic homeostasis [26] [27] [28] . In addition, we assessed the impact of casein kinase inhibition on melatonin and corticosterone secretion and wheel-running rhythmicity. The impacts on gene expression and hormone secretion were compared with those occurring following acute exposure to 4 h of light at the expected time of lights off, which was predicted to result in approximately a 3 h delay in the melatonin rhythm [29] .
Materials and methods

Animals and experimental design
Male albino Wistar rats (4 weeks of age on arrival) were obtained from the University of Adelaide Laboratory Animal Services Facility where they had been maintained on a 12L:12D photoperiod (lights off at 2000 h). The rats were then group housed (n = 5) in light-controlled environment chambers for 1 week with ad libitum access to food and water. The studies were approved by the University of Adelaide Animal Ethics Committee.
To investigate the effects of acute inhibition of casein kinase 1d/e on the expression of clock and other genes in the SCN, liver and pancreas, groups of rats were injected with PF-670462 (Lundbeck Research USA; 50 mg/kg; s.c.) or vehicle (20 % 2-hydroxypropyl-b-cyclodextrin; Sigma, St Louis, MI) just prior to the time of lights off (2000 h). The dose and timing of administration were chosen on the basis of previous dose response studies conducted in rats [21] . Following the injections, the lights remained off for the remainder of the experiment. Groups of rats were killed by rapid decapitation; 5 vehicle-treated rats at 2400, 0400, 0800, 1200, 1600 and 2000 h (4, 8, 12, 16, 20 and 24 h post treatment) and three rats at 2400, 0400 and 0800 h (28, 32 and 36 h post treatment); 10 PF-670462-treated rats were killed at 2400 and 2000 h (4 and 24 h post treatment) and 5 rats at the other times. Brain, liver and pancreas tissue were immediately dissected and placed in RNAlater Ò (Ambion, Texas, USA) for 24 h at 4°C and then stored at -20°C until processed. Blood was collected into heparinised tubes, centrifuged and plasma stored at -20°C.
To investigate the effects of an acute 4 h extension of the light phase on the expression of clock and other genes in the liver and pancreas, the lights in the environment chambers remained on until 2400 h and the rats thereafter remained in darkness until killed. For the control rats, lights were turned off as usual at 2000 h. Groups of 5 control rats were killed at 2000, 2400, 0400, 0800, 1200, 1600 and 2000 h (0, 4, 8, 12, 16, 20 and 24 h after lights off) and groups of three rats were killed at 2400, 0400 and 0800 h (28, 32 and 36 h after lights off). Light-exposed rats (n = 5 per time point) were killed at 4 hourly intervals from 2400 h. Liver, pancreas and blood were collected and stored as above.
RNA isolation and real time RT-PCR
Rat liver and pancreas tissue were homogenised in TriReagent (Sigma) using the PowerLyzer24 TM bench-top homogeniser (Mo Bio Laboratories Inc, Carlsbad, CA) at 6500 rpm (30 s 9 2, 30 s) and total RNA was isolated according to the manufacturer's instructions. For the brains, a 1-mm coronal section including the SCN was prepared using a Vibroslice (Campden Instruments, London, UK), placed on a slide and frozen on dry ice for approximately 2 min. SCN from both hemispheres were subsequently punched out using a modified 22-gauge needle and expelled into 100 ll RNAqueous lysis buffer (Ambion) [30] and stored at -20°C. The remaining brain sections were subsequently examined under a dissecting microscope to confirm that both SCN had been collected. Ambion RNAqueous Ò micro kits (Ambion) were used to extract RNA from the SCN samples, which were further processed as previously described [30] . Potential residual DNA was digested using a DNA-free kit (Ambion) according to the manufacturer's instructions. Punching of the SCN was not always successful and this together with occasional reverse transcription failures resulted in some time points having reduced data points.
Because of the small amount of tissue obtained from the punches, all of the extracted SCN RNA and 2 lg of the liver and pancreas RNA were reverse-transcribed using Super Script III (Invitrogen Corporation, Carlsbad, CA) according to the manufacturer's instructions, with a total reaction volume of 39 ll, made up to 100 ll following reverse transcription. After the addition of primers and SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA), genes of interest were amplified using a GeneAmp 7500 Sequence Detection System (Applied Biosystems) in duplicate, using primers designed and optimised in our laboratory ( Table 1) . The expression of genes within each sample was normalised against Actb, and expressed relative to a calibrator group (2400 h vehicle-treated rats or 2400 h control rats) using the formula 2 -(DDCt) .
Wheel-running behaviour
To assess the effects of PF-670462 on voluntary physical activity, rats were housed individually in cages fitted with running wheels (25 cm diameter) within light-controlled chambers. A data acquisition system (LabPro, Data Sciences, St. Paul, MN) was used to record the number of wheel rotations in 10 min bins. After 10 days acclimatisation to the running wheels, five rats were administered PF-670462 (50 mg/kg; s.c.) and five rats were vehicle treated at the time of lights off (2000 h). The rats then remained in continuous darkness for 9 days to determine the effects of the drug on the phase of their running rhythms. Periodograms were prepared using Actiview software (MiniMitter, Bend, OR) using data for the first to ninth days after treatment. The onset of activity (defined as the time when there were more than 10 revolutions/10 min) was then calculated for each of the first 8 days before and the 9 days after treatment for each rat and their times adjusted to account for the free-running periods. The differences between the averaged individual pre-treatment and post-treatment onsets were calculated and then the average shifts for the control and PF-670462-treated groups were determined.
Hormone assays
Melatonin was assayed in 250 ll plasma and assayed by double antibody RIA [31] (Buhlmann Laboratories, Allschwil, Switzerland) according to the manufacturer's instructions. Corticosterone was assayed in 10 ll plasma by double antibody RIA from MP Biomedicals Australia (Seven Hills, Australia) according to the manufacturer's instructions.
Statistics
The gene expression and hormone data were fitted to sine curves using CircWave; (http://hutlab.nl/ [32] ). For the determination of phase for both the PF-670462 and extended light experiments, only data from the last 24 h were used to eliminate any acute drug effects on gene expression. The time of peak expression refers to the acrophase when there was a significant (P \ 0.05) fit of the data to a sine curve with a period of 24 h and phase shifts are the differences between the acrophases. Differences in expression at each time point were analysed by 2-way ANOVA with post hoc Bonferroni tests.
Results
Effects of PF-670462 on the liver
During the 12 h following PF-670462 administration, the liver Bmal1 mRNA expression increased slower than in the control rats as dawn approached such that the peak was delayed by 7 h (Fig. 1 ). In addition, peak Bmal1 mRNA expression was almost twofold higher than the controls. Expression of Nr1d1 mRNA was also affected by the casein kinase inhibitor, with peak expression occurring 3.9 h later than the controls and the level of expression more than 50 % lower at the time of the peak. Following PF-670462 administration, the pattern of decreasing Per1 mRNA expression across the night and into the subjective light period followed that of the controls, but the subsequent increase towards the time of subjective lights off was slowed such that the time of peak expression was delayed by 1.2 h and the level of expression was approximately 50 % lower than the control rats ( Fig. 1 ;
001). A similar pattern of expression occurred for
Per2 and Cry2 mRNA but with a larger delay in the timing of peak expression (Table 2 ). Rhythmic expression of Cry1 mRNA was lost following PF-670462 treatment ( Fig. 1 ; P [ 0.05) with the level of expression lower than in the controls throughout the subjective night (P \ 0.05).
Effects of PF-670462 on the pancreas
In the pancreas, PF-670462 administration delayed the expected morning peak in Bmal1 mRNA expression by 7.2 h compared to the controls, but there was no difference in the level of expression at the time of the peak (Fig. 2) . The timing of the afternoon/evening peaks, but not the levels of expression of Nr1d1, Per1 and Per2 mRNA expression were delayed by up to 5.7 h ( Table 2) . While Cry1 and Cry2 mRNA expression was rhythmic in vehicletreated rats, the rhythm was lost following PF-670462 administration and Cry1 mRNA expression remained low throughout the subjective dark period ( Fig. 2 ; P \ 0.05).
Effects of PF-670462 on hormone secretion
Plasma melatonin was highest during the night and had decreased to its lowest level by 4 h after subjective lights on in the controls and increased again during the subjective night. PF-670462 administration had no impact on either the timing or the amplitude of the melatonin rhythm (Fig. 3a) . The pattern of plasma corticosterone in control and PF-670462-treated rats was similar until the subjective night when the time of peak secretion was delayed by 2.1 h (Fig. 3c) . The shaded area from 0800 h to 2000 h represents the subjective light period. *P \ 0.05; **P \ 0.01; ***P \ 0.001 Table 2 The time of peak expression of liver and pancreas genes and the changes in the peaks of vehicle treated, PF-670462 treated, control and light-exposed rats Effects of PF-670462 on the SCN Rhythmic expression of Bmal1, Nr1d1 and Dbp mRNA was apparent in the SCN punches from the control rats (Fig. 4) . For Per1 and Per2 mRNA expression, the data did not fit a sine curve, although highest expression occurred at the time of subjective lights off (2000 h) and 4 h before (1600 h), respectively. PF-670462 administration had no effect on either the timing or levels of Bmal1 mRNA (Fig. 4) . By contrast Nr1d1 and Dbp mRNA expression progressively decreased following PF-670462 administration to be lowest at the time of subjective lights on. Expression then increased such that the time of peak expression occurred 4.2 and 4 h later than the controls, respectively (Fig. 4) . Per2 mRNA expression progressively decreased following PF-670462 administration, to be lowest at 1000 h, and thereafter expression increased to reach a maximum at 2400 h. The timing and levels of Per1 mRNA expression were not altered by PF-670462.
Effects of PF-670462 on wheel-running behaviour
To investigate the effects of PF-670462 inhibition of casein kinase on circadian behavioural rhythmicity, rats were monitored for 9 days after administration of the drug. In the 8 days prior to treatment, all rats established consistent patterns of wheel running characterised by an onset of running activity within 20 min of the lights going off and a predominance of running during darkness. In the first 12 h following administration of PF-670462 or vehicle, the number of wheel revolutions was similar in both groups (873 ± 141 revolutions for the controls vs. 1,004 ± 119 revolutions for PF-670462 treated rats; P [ 0.05). The subsequent onset of running activity for the drug-treated rats was delayed, compared to the pre-treatment period (25 ± 9 min for the controls vs. 93 ± 14 min for PF-670462 treated rats; Fig. 5 ; P = 0.004).
The period of the free-running rhythm following the treatment was not altered (24 h 12 min for the controls vs. 24 h 7 min for PF-670462 treated rats; P [ 0.05). 
Effects of a 4 h extension of the light period on rhythms
Prolonging the light phase by 4 h resulted in no or small delays in the rhythm of expression of liver Bmal1, Per1, Per2 and Nr1d1 mRNA (Fig. 6 ). The mean delay of peak expression of these four genes was 0.8 ± 0.5 compared to 4.5 ± 1.3 h for the same genes following PF-670462 administration. The peak in liver Cry1 mRNA expression was delayed by 0.28 h, whereas Cry2 mRNA expression was not rhythmic in either control or light-exposed rats. In the pancreas, the expression of Bmal1, Per1, Per2 and Nr1d1 mRNA was delayed by 0.9 ± 0.5 h (Fig. 7) , compared to a delay of 4.5 ± 1.2 h for the same genes following PF-670462 administration. Cry1 and Cry2 mRNA expressions were delayed by 0.52 and 2.72 h, respectively, following the light exposure. Extension of the light period resulted in the suppression of the melatonin rise until 0400 h (Fig. 3b) but had no effect on the timing of peak secretion during the following subjective night (0430 vs. 0456 h). Following the light exposure, unlike the control rats, there was no clear plasma corticosterone rhythm (Fig. 3d) , but the highest levels of corticosterone in the two groups occurred at the 2000 h sampling time, suggesting that there was little effect of light.
Discussion
In the current study, we showed that administration of the casein kinase 1d/e inhibitor PF-670462 prior to lights off resulted in large delays (3.2-7.2 h) in rhythmic clock gene expression in peripheral tissues of rats (liver and pancreas). Smaller shifts in the expression of some clock genes were detected in SCN punches. Interestingly, there was no acute effect of PF-670462 on the secretion of melatonin or the timing of the rhythm the following night, whereas the corticosterone rhythm was delayed by 2.1 h. As expected, administration of PF-670462 delayed the onset of wheelrunning activity by approximately 1.1 h which is consistent with previous studies in rats at the dose used (50 mg/kg) [21] , although less than that reported in mice [24] .
In contrast to the liver and pancreas, the acute effect of PF-670462 treatment on the SCN was a steady suppression of Per1, Per2, Nr1d1 and Dbp mRNA expression over the initial 12 h. This is consistent with prolonged transcriptional repression of Bmal1 mRNA due to reduced phosphorylation of the Period and Cryptochrome proteins. Subsequent degradation of the proteins and loss of inhibition of the enzymes and translation of new enzyme protein would facilitate the resumption of transcription of Per1, Per2, Nr1d1 and Dbp. Interestingly, there was no effect of PF-670462 on Bmal1 mRNA expression levels or timing and changes in the timing of peak Per1 or Per2 mRNA expression in the SCN on the second subjective night were not clear. The rhythms of Nr1d1 and Dbp mRNA expression were, however, delayed. A recent study in mice reported similar shifts in Nr1d1, Dbp and Per2 mRNA expression in hypothalamic blocks following administration of PF-670462 (30-100 mg/kg) [24] . Small or no shifts were reported for Bmal1, Per1, Dec1, Nr1f2 and Prok2 mRNA. It is unlikely that the small changes are due to a lack of a central effect of the drug since PF-670462 is reported to have good brain penetrance and a short half-life (approximately 30 min) [21] . Furthermore at the concentration used in this experiment, it may be predicted from pharmacokinetic and in vitro studies in rats and mice that most of the casein kinase 1d/e activity would be inhibited for several hours [21, 23] . The inhibitor used in the current study has been reported to affect the two casein kinase enzymes casein kinase 1d and casein kinase 1e differently [23] . While the relative levels of the enzymes in various tissues are not known, it is possible that the different phase delays apparent in the SCN and the peripheral tissues studied is a reflection of variations in the degree of inhibition of phosphorylation of the clock proteins. Limitations of the current rat and the previous mouse studies are that the tissues included both core and shell regions of the SCN which have quite different functions [33] . Furthermore, the amount of RNA obtained from the SCN punches is quite low and can result in greater variability in RT-PCR results and loss of statistical power to detect rhythm changes. The failure of PF-670462 to change the timing of the plasma melatonin rhythm, in contrast to the 1.1 h delay in wheel-running activity is interesting and consistent with the relatively small change in SCN function. Another consideration is that the 4 h sampling interval and curve fitting approach may not be optimal for determining small shifts of melatonin secretion.
A secondary aim of the current study was to compare the effects of the inhibition of casein kinases with the effects of an extension of the light period by 4 h. We have previously shown that a 6 h light extension resulted in a 3.7 h delay in the nocturnal rise of urinary 6-sulphatoxymelatonin on the following subjective night [10] . In mice exposed to a 6 h light extension, there was induction of SCN Per2 and Cry1 mRNA expression, (but not Per1 mRNA), followed by a 6 h delay in the expression rhythm [34] . We reasoned that prolonged light would suppress melatonin secretion, phase delay the melatonin rhythm the next night and delay clock gene expression in the liver and pancreas. As predicted, prolonging light exposure suppressed the normal nocturnal rise in melatonin secretion, with high levels only appearing at 0400 h, but no subsequent delay in peak secretion was detected, perhaps in part due to the 4 h sampling that was used. Nevertheless, the changes in liver and pancreas gene expression rhythms following light exposure were smaller than those following PF-670462 administration. Although we did not analyse clock gene expression in the SCN of the rats following light exposure, the minimal changes in timing of the pineal melatonin rhythm and the liver and pancreas gene rhythms suggests that acute inhibition of casein kinase has a more powerful impact on the SCN than 4 h of light and that the response is greater in peripheral tissues.
There are some limitations in the current study. We did not investigate the effects of PF-670462 on casein kinase enzyme activity following administration and so must rely on previous studies that have shown that this compound does indeed prevent phosphorylation of key clock proteins. The study was conducted at a single dose (50 mg/kg) which was shown previously to not produce maximum phase shifts in rats. Higher doses of PF-670462, for example 100 mg/kg, resulted in delays in the onset of wheel running of up to 4 h in rats [21] . However, in preliminary gene expression studies at this higher dose, we observed that three of 15 rats died within 12 h of administration (Kennaway, unpublished results) . This toxicity has not been observed previously (Dr Jeffrey Sprouse, personal communication), but we were compelled to use the lower dose. The study did not address the impact of the changes in liver and pancreas clock gene rhythmicity on the function of these organs, for example the impact on rhythms of glucose tolerance and insulin sensitivity, but this is an area that will be pursued in the future. Finally it would be very interesting to know how long the clock gene changes in the liver and pancreas persist and whether chronic administration would bring about larger shifts in rhythmicity as has been observed in behavioural studies in mice [24] and rats [22] , although limited access to and the high price of the drug may limit these types of study in rats. The development of drugs that alter the intrinsic timing system of cells is opening up an exciting new area of pharmacology with important potential applications. One such possibility is that the drugs could be used to facilitate the adaptation of shift workers to their artificial lifestyle of nocturnal wakefulness and meals and diurnal sleep opportunities. This may help to lower the risk of developing the shift work-related metabolic and cardiovascular disorders that are increasingly being reported [35, 36] . In the current study, acute administration of PF-670462 caused phase shifts in gene expression simultaneously across central and peripheral tissues as well as the previously documented change in behavioural rhythmicity. Future studies should investigate the long term impact of the alterations in liver and pancreas function following acute and chronic administration of these drugs to Fig. 6 The expression of Bmal1, Per1, Per2, Nr1d1, Cry1 and Cry2 mRNA in the liver of rats exposed to 4 h extended light at the beginning of the dark period (light shaded area), followed by continuous darkness to the remainder of the experiment. The data for the control rats are shown as filled symbols and continuous lines while data from light-exposed rats is represented by open symbols and broken lines. Data are displayed as for Fig. 1 . *P \ 0.05; **P \ 0.01; ***P \ 0.001 determine if there are adverse effects of rapidly phase shifting rhythms in this manner.
In conclusion, acute administration of the casein kinase inhibitor PF-670462 to rats at the beginning of the dark period resulted in small delays in clock gene rhythms in the SCN and corticosterone secretion and had no effect on melatonin secretion. The small changes in gene expression observed in the SCN may, however, be due to the incorporation of both core and shell regions of the SCN in the punches. By contrast, there were large phase delays in clock gene rhythms in the liver and pancreas. The effects of acute casein kinase inhibition on liver and pancreas rhythmicity were considerably greater than the effects of a 4 h light extension. Fig. 7 The expression of Bmal1, Nr1d1, Per1, Per2, Cry1 and Cry2 mRNA in the pancreas of rats exposed to 4 h extended light at the beginning of the dark period. The data for the control rats are shown as filled symbols and continuous lines while data from light- 
